JavaScript is required to use content on this page. Please enable JavaScript in your browser.
The Prescription Drug Affordability Board is an independent unit of state government tasked with protecting Marylanders and the Maryland health care system from the high costs of prescription drug products.
UPCOMING MEETING: Prescription Drug Affordability Board Meeting, March 23, 2026 at 2:00 PM. Meeting information can be found here.
Draft Proposed Regulations for Comment (Posted: 3/16/2026): The PDAB is soliciting comments on draft UPL regulations for Farxiga and Jardiance under COMAR 14.0101.05B(4). Please visit the proposed regulations page for more information. Comments are due March, 30, 2026 to [email protected]
Written Comment Request: Draft Cost Review Study Reports (Posted March 16, 2026). In accordance with COMAR. 14.01.04.05F(3), staff has posted the draft Jardiance Cost Review Study Report and the Farxiga Cost Review Study Report and is requesting public written comment. Comments may be submitted in accordance with COMAR 14.01.01.05B(4) by close of business, Monday, March 30, 2026. More information can be found here.
Data Request: The Maryland Prescription Drug Affordability Board may require covered entities and 340B manufacturers to report information as necessary to complete a study on the implementation, impact, and finances of the 340B program in Maryland, as outlined in 2024 Md. Laws, Chap. 962 (HB 1056). Please see the Data request webpage for more information. Information should be submitted by April 10, 2026 to [email protected].
We're available on the following channels.
